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German-Austrian recommendations for HIV1-therapy
in pregnancy - Update 2008
Bernd Buchholz (University MedicalCentre Mannheim,
Pediatric Clinic), Matthias Beichert (Mannheim, Gyne-
cology and Obstetrics Practice), Ulrich Marcus (Robert
Koch Institute, Berlin), Thomas Grubert, Andrea Gin-
gelmaier (Gynecology Clinic of the Ludwig Maximil-
ians University of Munich), Dr. med. Annette Haberl
(HIV-Department, J. W. Goethe-University Hospital,
Frankfurt), Dr. med. Brigitte Schmied (Otto-Wagner
Spital, Wien).
In Germany during the last years about 200-250
HIV1-infected pregnant women delivered a baby each
year, a number that is currently increasing. To deter-
mine the HIV-status early in pregnancy voluntary
HIV-testing of all pregnant women is recommended
in Germany and Austria as part of prenatal care. In
those cases, where HIV1-infection was known during
pregnancy, since 1995 the rate of vertical transmission
of HIV1 was reduced to 1-2%.
This low transmission rate has been achieved by the
combination of anti-retroviral therapy of pregnant
women, caesarean section scheduled before onset of
labour, anti-retroviral post exposition prophylaxis in
the newborn and refraining from breast-feeding by the
HIV1-infected mother. To keep pace with new results
in research, approval of new anti-retroviral drugs and
changes in the general treatment recommendations for
HIV1-infected adults, in 1998, 2001, 2003 and 2005 an
interdisciplinary consensus meeting was held. Gynae-
cologists, infectious disease specialists, paediatricians,
pharmacologists, virologists and members of the Ger-
man AIDS Hilfe (NGO) were participating in this
conference to update the prevention strategies. A fifth
update became necessary in 2008. The updating
process was started in January 2008 and was terminat-
ed in September 2008. The guidelines provide new
recommendations on the indication and the starting
point for HIV-therapy in pregnancies without compli-
cations, drugs and drug combinations to be used
preferably in these pregnancies and updated informa-
tion on adverse effects of anti-retroviral drugs. Also
the procedures for different scenarios and risk constel-
lations in pregnancy have been specified again.
With these current guidelines in Germany and Aus-
tria the low rate of vertical HIV1-transmission should
be further maintained.
Key words: Pregnancy, HIV-therapy, HIV-status,
HIV-testing, anti-retroviral drugs, recommendations
INTRODUCTION
The German-Austrian recommendations for HIV1-
therapy in pregnancy reflect the current international
knowledge and the experience of German clinical set-
tings specialized in the treatment of HIV1-positive
pregnant women.
Even though all constellations, scenarios and con-
tingencies of a pregnancy can not be considered with-
in the scope of these recommendations, they are de-
signed as scientifically-based guidelines. The most im-
portant and most frequent questions and problems
which doctors, who treat HIV1-positive expectant
mothers are facing, irrespective of whether they are
experienced in the care for such pregnancies or not,
are covered in these guidelines.
The medical measures recommended in these
guidelines are helpful for every health care profession-
al, who advises a HIV1-positive pregnant woman.
Therefore these recommendations should be
available in every delivery room. In case of obstet-
ric emergencies the tables of these recommendations
can be used as emergency plan.
It is also urgently recommended, that an HIV
post-exposure prophylactic emergency set be kept
in stock by the hospital and that all medical per-
sonnel involved is informed about indications and
procedures related to HIV post-exposure prophy-
laxis after occupational HIV1-exposure (e.g. fol-
lowing needle prick or knife injuries to the operat-
ing surgeon).
Therapeutic recommendations can never replace
extensive experience with patients and their specific
problems. Therefore antenatal care of HIV1-positive
expectant mothers, considering the many uncertainties
associated with pregnancy, should be performed in -
or in cooperation with specialized centers.
Without any medical measures to prevent mother to
child transmission of HIV1 up to 40% of the HIV1-
exposed newborn are HIV1-infected. In those cases,
where HIV1-status of the pregnant women was
known during pregnancy, since 1995 the rate of verti-
cal transmission of HIV1 was reduced to 1-2% in
Germany and Austria [140]. This low transmission rate
has been achieved by the combination of anti-retrovi-
ral therapy of pregnant women, caesarean section
scheduled before onset of labour, anti-retroviral post
exposition prophylaxis in the newborn and refraining
from breast-feeding by the HIV1-infected mother.
All measures necessary for the prevention of vertical
HIV1-transmission can only be employed, if the HIVin-
fection status of the expectant mother is known. Risk
factors for an HIV-infection, such as origin from a an
HIV epidemic region, current or previous intravenous
drug abuse or sexual intercourse with an HIV-infected
partner, can not always be identified amongst all preg-
nant HIV1-infected individuals. For that reason an
HIV antibody test should be offered to every preg-
nant women together with competent personal coun-
seling in regard to possible consequences in the case of
a positive test result (see also in 2007 updated German
prenatal care guidelines und the therefore created leaflet
“HIV-testing in pregnancy” as information of all preg-
nant women). If necessary this must be carried out with
an interpreter and cultural mediation, eveni fthe patient
needs to be referred to a specialized center for this pur-
pose. By German law the explicit approval of the preg-
nant mother is required for HIV-testing, which routine-
ly consists of an ELISA screening test. A positive test
result must be confirmed by Western Blot [1, 2]. If the
patient is counseled by her gynecologist alone, address-
es and telephone numbers of additional experts should
be made available to the expectant mother. The person-
al and medical consequences of any positive test result
for the woman should also be discussed in the counsel-
ing. Furthermore a competent pediatrician should con-
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low-up tests and the course of HIV1-infectioni nachild.
As with many other problems in pregnancy, the
welfare of the child must be weighed up against that
of the mother when deciding for therapeutic/pro-
phylactic measures against HIV1.
The goals of interdisciplinary co-operation between
general practitioners, obstetricians and pediatricians in
the treatment of HIV1-infected expectant mothers
and HIV1-exposed newborns are: 1) the prevention of
mother to child transmission of HIV, and 2) the opti-
mal treatment of pregnant women combined with
minimal adverse effects in the expectant mother and
in the unborn child.
Mothers with a high viral load and/or low t-helper
cell numbers transmit HIV1 more frequently to their
children [3, 4, 5], therefore successful therapy of the
mother is also beneficial for the child. Risks for the
child that might arise from intrauterine exposure to
anti-retroviral combination therapies are still uncertain
since data regarding pharmacokinetics, pharmacody-
namics, embryotoxicity and fetotoxicity of these drugs
are lacking [6, 7, 8, 9, 10, 11, 12, 13].
Basic and clinical research data suggest multiple risk
factors which contribute to vertical HIV1-transmis-
sion [3, 4, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25].
Combined interventions as described in the following
chapters can reduce the HIV1-transmission rate below
2% [16, 26, 27, 28].
The recommendations for diagnostic and therapeu-
tic procedures given here are based on published study
results wherever these were available. Such study re-
sults, however, are not available for all practical prob-
lems and questions, so that often clinical experience
and expert opinions must be resorted to.
Even if the goal of these recommendations is the
optimal treatment of mother and child based on the
most recent findings, it should be stressed that the de-
cision for the recommended diagnostic and therapeu-
tic measures ultimately must be made in agreement
with the expectant mother. This means that a refusal
of a recommended diagnostic and/or therapeutic
measure must also be respected, wherever the consent
of an expectant mother can not be acquired despite
adequate counseling.
After a detailed analysis of data and publications, a
number of procedures were developed for specific sit-
uations. Most common situations and scenarios were
considered. For all other situations however, individual
decision on a case-by-case basis are necessary.
The following situations were discussed and con-
sensus recommendations were made:
1. Prenatal care
2. Indication for anti-retroviral treatment and therapeutic
regimens during pregnancy
2.1 Indication for anti-retroviral treatment
2.2 Resistance testing
2.3. Initial therapeutic regimen
2.4. Management of HIV1-positive pregnant women with
Hepatitis-co-infection
2.4.1 Management of HIV1-positive pregnant women with
Hepatitis B virus (HBV) co-infection
2.4.2 Management of HIV1-positive pregnant women with
Hepatitis C virus (HCV) co-infection
2.5 Interruption of anti-retroviral therapy during the 1st
trimester of the pregnancy
3. HIV1-transmission prophylaxis with standard risk pro-
file
4. Risk-adapted transmission prophylaxis
4.1 Multiple pregnancy, premature labor and premature in-
fants 33rd(+0) - 36th(+6)GW and maternal viral load
3000- 10000 HIV-copies/ml before birth
4.2 Amnion infection syndrome/amnionitis, (premature)
rupture of membranes >4h, premature birth <33rd(+0)
GW and viral load increase at the end of pregnancy
>10 000HIV copies/ml
4.3 Incision injury of the child/ aspiration and/or
ingestion of blood contaminated amniotic fluid
5. Procedures with incomplete transmission prophylaxis
5.1 With verified HIV1-infection
5.2. Situations with unclear HIV1-infection status
6. Mode of delivery
7. Postnatal care in the delivery room
8. Postnatal prophylaxis of the newborn
9. Refraining from breast-feeding
10. Postnatal care of the HIV1-exposed child and prepara-
tion of a surveillance register
11. Phone-Hotline, notification of unexpected observa-
tions and experiences
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Table 1. Grading of the therapeutic recommendations.
I II III
On the basis of at least one On the basis of surrogate According to expert
randomized study with marker studies opinion
clinical end points *
A Unambiguous recommendation A I A II A III
B In general advisable B I B II B III
C Justifiable C I C II C III
D In general not recommended D I D II D III
E Unambiguously not recommended E I E II E III
* Clinical end point studies for new substances are no longer carried out due to the fact that conditions for licensing by the
FDA and the EMEA have changed
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the German-Austrian guidelines for the anti-retroviral
Therapy of HIV1-infection [29]. Unless the results of
voting are indicated, the recommendation was agreed
upon unanimously.
1. PRENATAL CARE
Upon diagnosis of HIV1 in a pregnant woman, an in-
terdisciplinary center specialized in HIV care should be
contacted immediately. From that point onwards the
woman should be treated in close cooperation with the
gynecologist familiar to the pregnant women. The gy-
necologist, who usually treats the women, is primarily
recommended to carry out the conventional prenatal
care for HIV1-positive pregnant women, according to
current antenatal care guidelines, to preserve the bond
with the patient’s familiar environment. Any other ad-
ditional care measures should also be fitted in this set-
ting. With the help of a well-planned time scheduling a
closely-knit monitoring can be ensured.
Psychosocial care should be provided to each
HIV1-positive expectant mother, at the latest in the
HIV-specialized centers, and the opportunity to con-
tact women’s AIDS self-help groups should also be
offered. In the HIV-specialized centers the patients
should be fully counseled regarding maternofetal
transmission risks, current therapeutic options, the
possibility to reduce mother-to-child HIV1-transmis-
sion rates, existing residual risks, potential short - and
long-term effects of intrauterine exposure to anti-
retroviral therapy for the child as well as the necessity
of postnatal prophylaxis in the child and of avoiding
breast-feeding. [30, 31, 32]. Considering the rapidly de-
veloping state of knowledge regarding HIV, up to date
information is only warranted in such specialized cen-
ters. To overcome language barriers the help of inter-
preters should be obtained wherever necessary to en-
sure that all information reach the patients.
In co-operation between the general practitioner,
the gynecologist, the obstetrician, the pediatrician and
the patient, an individual, risk-adapted anti-retroviral
treatment or prophylaxis concept corresponding to
current German-Austrian guidelines for therapy in
pregnancy should be set up. The general practition-
er/infectious disease specialist should be consulted to
adapt this therapeutic plan to ongoing therapies or
prophylaxes against opportunistic infections. A
switching of the treatment regime during pregnancy
or the initiation of new therapeutic measures should
only be undertaken upon consultation with a physician
or center specialized in anti-retroviral therapy.
In the case of therapy-refractory morning sick-
ness/emesis gravidarum all anti-retroviral medications
should be stopped simultaneously (An interruption of
a combination of 2NRTI + NNRTI is problematic:
Because of their short half-value period the 2NRTI
disappear very fast after simultaneous interruption. In
contrast to them the NNRTI has a longer half life
with a high interindividual variability. NNRTI can be
detected up to 3-4 weeks after interruption in some
patients [141], which after disappearance of NRTI’s
implies a monotherapy with a high risk of develop-
ment of resistance. See also 2.5) and reintroduced si-
multaneously, if the symptoms start to improve again
in order to prevent the development of resistance
anti-retroviral drugs (AIII).
Concurrently with the therapy, a monthly monitor-
ing of blood counts is also recommended (AIII).
Changes in blood counts are particularly significant
because of the possibility of zidovudine-induced ane-
mia and thrombocytopenia. If the hemoglobin-values
drop to less than 10mg/dl in the expectant mother, it
must be decided in close cooperation with the general
practitioner whether waiting with closely-knit controls
is possible or if the anti-retroviral regimen must be
changed.
An oral glucose tolerance test is recommended be-
tween the 23rd (+0) and 27th (+7) weeks of gestation
(GW) to screen for pregnancy-related diabetes, partic-
ularly if the expectant mother is treated with protease
inhibitors (under protease inhibitor therapy diabetes
mellitus occurs approximately three times more fre-
quently) [33] (AIII). Measurements of blood lactate,
liver enzymes, lipase and LDH should be carried out
at the beginning of the pregnancy, after starting a ther-
apy or prophylaxis, with suspicious clinical symptoms
(signs of lactate acidosis such as nausea, severe vomit-
ing, abdominal pain, fatigue, raised liver values) and
particularly in the 3rd trimester because of the in-
creased risk of lactate acidosis at the end of pregnancy
(AIII).
Immunological and virological parameters (lympho-
cyte subsets, HIV1 viral load) should be checked at
least bimonthly (AIII). The last measurement of
HIV1-viral load before birth should be performed in
time (2-4 weeks before birth), that the result is known
at the latest at birth. In the case of an increased HIV1-
viral load of the mother it is possible to intensify the
anti-retroviral prophylaxis of the HIV1-exposed new-
born to reduce the increased risk of vertical HIV1-
transmission (see also 4.2) [72].
The expectant mother should be informed about
any possible side effects and symptoms of the anti-
retroviral therapy and should also be requested to in-
form their general practitioner immediately of any
suspicious complaints [34, 35, 36]. Furthermore, she
should also be requested to consult her general practi-
tioner before taking any other prescribed or OTC
medications during the pregnancy because of potential
interactions with the anti-retroviral therapy (e.g. ben-
zodiazepines).
Especially HIV1-positive pregnant women on
methadone substitution or with drug abuse should be
informed in detail about drug interactions between
these drugs and anti-retroviral therapy/prophylaxis.
Without continuous medical evaluation anti-retroviral
therapy can lead to withdrawal syndrome, which jeop-
ardize success of anti-retroviral therapy due to lack of
adherence.
A comprehensive diagnostic evaluation and therapy
for genital infections is also important. Local co-infec-
tions such as chlamydiasis, trichomoniasis and bacteri-
al vaginosis amongst others correlate with higher
HIV1-transmission risks, especially due to potential in-
duction of premature labor [24]. The following exami-
nations are obligatory: determination of vaginal secre-
tion pH; sampling of a native preparation and micro-
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Table 1. (Additional) Diagnostic measures during a uncomplicated HIV1 pregnancy.
Diagnostic measure Timepoint/ frequency Reason
HIV-screening and if necessary - routinely in the 1st trimester in case Precondition for therapeutic measures to
HIV-confirmative test of unknown HIV1-status; reduce the risk of vertical HIV1-transmission
- at the start of the 3rd trimester after
negative initial test but continuous risk
of infection
CD4 cell count + viral-load At least every two months Monitoring the course of the HIV1-infection;
Initiation of ART or switchover of ART in
case of therapeutic failure
Control of the efficacy of the (HA)ART to
prevent a high HIV1-viral load at birth
HIV1-resistance test 1. As early as possible before the onset 1. Exclusion of a primary ZDV resistance
of prophylaxis [38, 39, 40, 41]
2. In case of virological therapy failure 2. According to general therapeutic recom-
during an ART mendations for optimizing a therapeutic
switchover [29]
3. With detectable viral load towards 3. Registration of any possible resistance
the end of an HIV1-prophylaxis induction that might have implications for a
future therapy [42]
4. 2-6 weeks after application of a 4. Documentation of a potential resistance
prepartal NVP ultra-short prophylaxis induction [43, 44]
Blood count Monthly Detection of anemia, thrombopenia related to
(Hemoglobin value) the use of ZDV in particular
Oral glucose tolerance test Between 23rd (+0) and 27th (+6) weeks Detection of gestation diabetes
of gestation
Lactate level + liver values + 1. At the start of pregnancy Recommended for detecting lactic acidosis
γGT + LDH + lipase 2. After onset of therapy/prophylaxis (raised incidence in the 3rd trimester).
3. In case of clinical symptoms Discussion of raised lactate and other values
4. Monthly in the third Trimester in cooperation with clinicians experienced
in carrying out and analyzing lactate measure-
ments.
pH measurement in the vaginal Recognition and timely treatment of local
secretion co-infections that can increase the risk of
Native preparation HIV1-transmission
Microbiological culture
STD-diagnostics: Chlamydia,
gonorrhea, trichomonas, syphilis
hepatitis serology
Toxoplasmosis screening At the start of a pregnancy as well as in For the diagnosis of a new infection or a
the 2nd and 3rd trimesters toxoplasmosis reactivation
Colposcopy, cytological controls Colposcopy, cytological examination and Increased risk of dysplasia with HIV1-
for vulvar, vaginal and cervical HPV-testing at the start of a pregnancy; infection [37]
dysplasias, HPV-testing If abnormalities are revealed, colposcopic
controls and wherever necessary histolo-
gical clarification (biopsy)
Measurement nuchal translucency 10th (+6) – 13th (+6) week of gestation Estimation of the risk of aneuploidy
Sonography,
at least DEGUM stage 2 19th (+6) – 22nd (+6) week of gestation Exclusion of malformations
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screening at the start of therapy and in the second and
third trimester to exclude a reactivation and/or new
infection at the end of the pregnancy; a complete he-
patitis serology. Urinary tract infections should be ex-
cluded e.g. by Uricult examinations.
Up to 30% of HIV1-infected women display vul-
var, vaginal and cervical dysplasias, which can progress
more rapidly to carcinoma as a result of the HIV1-in-
duced immune suppression [37]. For this reason a col-
poscopic examination should be carried out at the on-
set of pregnancy in addition to pap smear testing of
the cervix and HPV-testing for high-risk-HPV-sub-
types. If the colposcopic examination and HPV-test-
ing yield normal results, the next control examination
can be scheduled in a postnatal appointment. Any ab-
normalities must be controlled colposcopically and if
necessary histologically (AIII). The perianal region
should be examined in addition to the vulva, vagina
and cervix, as also recommended for non-pregnant
HIV1-infected women.
For all HIV1-infected expectant mothers nuchal
translucency/transparency of fetus should be mea-
sured between the 10th (+6) and 13th (+6) weeks of
gestation to estimate risks of aneuploidy. Fetal sonog-
raphy (at least DEGUM stage 2) should be carried out
between the 19th (+6) and 22nd (+6) weeks of gesta-
tion to screen for fetal malformations.
Invasive prenatal diagnostics should be avoided
whenever possible. If there is an urgent indication, it
should be performed with consideration of viral load
and only under the protection of anti-retroviral
therapy/prophylaxis because of the risk of contami-
nation of the amniotic fluid [110,111] (AIII).
If the HIV-status of the mother is unknown and
invasive prenatal diagnostic is indicated, an HIV-test
should be offered again.
6-8 weeks after birth a detailed counseling
about contraceptional methods is obligatory.
2. INDICATION FOR ANTI-RETROVIRAL
TREATMENT AND THERAPEUTIC REGIMENS
DURING PREGNANCY
2.1 INDICATION FOR ANTI-RETROVIRAL TREATMENT
Treatment indications [30] for adult HIV1-patients
also apply to pregnant women (but check 3.1b!!), i.e. in
clinically asymptomatic women the immunological
threshold for treatment is reached at a CD4-cell count
below 350 CD4+ cells/mm3. It should be noted here
that a certain degree of immunosuppression is in-
duced physiologically by a pregnancy [20, 47] so that
the CD4-values drop by around 10-20% during every
pregnancy. In an HIV1-infected woman, this effect is
may be even more pronounced (up to 40%). (AIII)
2.2 RESISTANCE TESTING
In order to ensure the efficacy of anti-retroviral pro-
phylaxis/ therapy during pregnancy, testing for pre-
existing resistance is generally indicated for every
treatment naive pregnant woman before the start of
anti-retroviral therapy or - prophylaxis [38, 39] (AIII).
For women who become pregnant during anti-retro-
viral treatment, German-Austrian guidelines for HIV1-
therapy in adults recommend resistance testing (AIII)
whenever a virological treatment failure is diagnosed.
If at the end of anti-retroviral HIV1-transmission
prophylaxis (determined just before - or directly at the
time of birth) viral load is detectable in pregnant
women, resistance testing should also be performed in
order to document the eventual development of resis-
tance under prophylaxis, so that this can be taken into
account if the woman requires anti-retroviral therapy
at a later timepoint [41] (AIII).
If nevirapine ultra-short prophylaxis (single mater-
nal dose immediately before birth) is given, resistance
testing should be carried out 4-6 weeks after the anti-
retroviral medication was stopped (see points 4 and 5)
in order to determine, whether resistance against nevi-
rapine has been induced [43,44] (AIII).
2.3. INITIAL THERAPEUTIC REGIMEN
(see Table 2)
Apart from the inhibition of viral replication in the
mother, a major objective of an optimized initial ther-
apeutic regimen during pregnancy is to combine an ef-
fective prophylaxis against HIV1-transmission with
the highest possible degree of compatibility for moth-
er and fetus. Restriction of subsequent maternal thera-
peutic options e.g. because of development of drug
resistance should also be avoided.
A standard therapeutic regimen is usually a triple
combination including two NRTI + either one (if nec-
essary boosted) protease-inhibitor or + Nevirapin is
recommended as an initial maternal therapeutic regi-
men[29] (AI,II). Efavirenz was excluded due to the re-
ports of cerebral malformations in the newborns of
efavirenz-treated pregnant monkeys [45]. Because 3
children with myelomeningoceles and one child with
Dandy-Walker-malformation were born to women af-
ter treatment with Efavirenz in pregnancy[138], mean-
while Efavirenz was reclassified as FDA pregnancy cat-
egory D. In addition, nucleoside analogues of particu-
larly high mitochondrial toxicity (i.e. dideoxycytidine
(ddC), stavudine (D4T) and didanosine(DDI)) should
not be given in combination with one another wherev-
er possible, because of the raised risk of a potentially
fatal lactate acidosis in the expectant mother [46] (AIII).
It has to be considered that with the exception of
zidovudine, no anti-retroviral drug has been approved
for therapy during pregnancy and that the limited ex-
perience until now has not permitted any definitive
evaluation of the risks and benefits. When choosing
anti-retroviral drugs one must also keep in mind that
the pharmacokinetics of each drug group (NRTI,
NNRTI+PI) can be altered during pregnancy [48, 49,
50]. Therefore during use of PI and NNRTI in preg-
nancy drug monitoring is compulsory.
2.4. MANAGEMENT OF HIV1-POSITIVE PREGNANT
WOMEN WITH HEPATITIS CO-INFECTION
It is urgently necessary to treat hepatitis-/HIV-co-in-
fected pregnant women in an interdisciplinary setting
including an infectious disease specialist.
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Table 2. Comments on the initial anti-retroviral combinations/substances.
Initial combinations and substances Comment
Nucleoside analogs Zidovudine + Lamivudine Most clinical experience has been gained with the use of these substances.
for which most ex- (also as Combivirﾮ) One additional rationale for application of zidovudine is the metabolization
perience has been of this drug in the placenta which might contribute to the transmission pre-
gained venting effect [51,52].
Some cases of lethal mitochondriopathies were reported in non infected
children after maternal zidovudine/lamivudine-therapy [7, 8]. Data about
long term toxicity especially carcinogenicity/genotoxicity as a matter of in-
corporation of nucleoside analogs into DNA [112] are lacking. In case of
therapeutic failure changed pharmacokinetics of nucleoside analogs because
of pregnancy must to be taken into consideration [113].
Alternatives Stavudine + Lamivudine Less clinical experience in pregnancy. Increased attention relating to poten-
Zidovudine+Didanosine tial side effects.
Didanosine +Lamivudine
Abacavir Use of Abacavir only after testing for HLA-B*5701[136] to avoid
hypersensitivityreaction. So far no increased rate of malformation in
humans [57], but individual reports of malformations [67].
Tenofovir: In animal studies, where Tenofovir was applied in higher doses than
usual in humans, reduced bone density and renal damage were
observed [135].
NNRTI Nevirapine: Caution: raised liver enzymes, more allergic reactions since pharmacokine-
tics are altered during pregnancy [49]. Increased liver toxicity in pregnancy
especially with CD4-counts >250/µl. With longer administration enzyme
induction of the cytochrome P450 system and therefore accelerated meta-
bolization of nevirapine not only in the expectant mother but also in the
newborn [53]. A single normal dose applied before birth and to the new-
born is therefore not sufficient for prophy laxis of HIV1-transmission, if
nevirapine has already been given over a longer period during the course of
the pregnancy.
Protease inhibitors, In common: Because of the poor ability of most PIs to cross the placenta (no or poor
for which most data: Fos-Amprenavir [57, 113, 125], Darunavir [57, 113], Tipranavir,)
experience has been no therapeutic levels are to be expected in the fetal compartment [54,55,56].
accrued [50]: As such, no relevant adverse effect frequency is to be expected amongst the
fetuses, but it is still unclear whether therapeutic drug-levels in the fetus are
necessary or helpful to inhibit vertical HIV1-transmission.
Lopinavir + Ritonavir No increased rate of malformations in humans [57, 126]
(=Kaletraﾮ) or
Saquinavir (Fortovaseﾮ) Until now rare published studies about the use in pregnancy [54, 57, 113]
+ Ritonavir but as yet no incidence for unusual or unexpected adverse effects [57].
Alternatives: Nelfinavir Up to now most experiences in pregnancy have been accrued for Nelfinavir
[57, 113, 126], but an anti-retroviral therapy with an unboosted PI is no more
recommended as optimal therapeutic regimen in adults [29].
Ritonavir Contraindicated as a mono-PI because of poor compatibility; can be applied
at low doses to boost plasma levels of other PI's.
Indinavir + Ritonavir High number of tablets, relevant side effects [57]. With Indinavir there is an
increased need for water uptake to prevent the formation of kidney stones
in the mother.
New substances: T-20 (fusion inhibitor) Should only be used in heavily pretreated pregnant women as part a of anti-
retroviral salvage therapy based on resistance testing. Because of the high
molecular weight a transplacental passage is not expected and could so far
not proved [121]. Some case reports show no adverse effects [57, 127].
Atazanavir Insufficient data for use in pregnancy [28, 57, 113], does not cross placenta
[127].
Emtricitabin As yet at the most single case reports [80], no recommendation due to the
Fosamprenavir risk of malformations possible [57].
Tipranavir
Darunavir
Maraviroc
Raltegravir
1. HIV in Pregnancy:Umbruchvorlage  15.10.2009  12:31 Uhr  Seite 467EUROPEAN JOURNAL OF MEDICAL RESEARCH 468 November 3, 2009
Table 3.1. Prevention of maternofetal HIV1-infection during a normal course of pregnancy.
Status of No ART before pregnancy ART before pregnancy
expectant Therapy indication according to German-Austrian guidelines for the
mother: therapy of HIV1-infection (30)
Indication: CD4 >350/µl CD4 >350/µl A) Clinical disease Women is getting pregnant while
and HIV1-RNA and HIV1-RNA ategory B + C or receiving an anti-retroviral
<10 000 >10,000 B) CD4 <350/µl combination therapy
HIVcopies/ml HIVcopies/ml
Maternal NO NO YES YES
treatment
indication
Fetal indi- YES YES (prophylaxis with YES YES
cation for (prophylaxis with raised maternal
prophylaxis standard risk) transmission risk)
Therapy: Resistance testing to exclude primary ZDV resistance
1st -13th
week of Invasive prenatal diagnostics only under anti-retroviral therapy/ prophylaxis
gestation (perform only if absolutely indicated)
No ART A) Immediate initiation of ART A) Interruption of ART if clinical,
At least bimonthly monitoring immunological and virological
At least bimonthly monitoring of CD4 + VL of CD4 / VL status of the mother allows
Switch of ART in case of (CAVE: Interruption of NNRTI
Start of ART in case of urgent maternal therapeutic failure with long half-life !!!)
treatment indication (see above) or At least bimonthly monitoring of
CD4 and VL
Invasive prenatal diagnostics (strictly B) Initiation of ART after week Immediate restart of ART in
indicated !) only under anti-retroviral therapy/ 13, depending on the urgency case of urgent maternal
prophylaxis of the maternal treatment treatment indication or
indication (see below). B) Otherwise continuation of
At least bimonthly monitoring ART, if necessary substitution of
of CD4 +VL efavirenz; substitution of
Start of the ART before week stavudine + didanosine if given
13 in case of urgent maternal in combination
treatment indication At least bimonthly monitoring of
CD4 and VL
Therapy: Beginning/ restart of ART e.g. with ZDV + 3TC/ ddI +
14th – 30th PI / NVP or premedication,
week of if possible without EFV or d4T+ddI,
gestation
At least bimonthly monitoring of CD4 and VL,
Therapy: A) ZDV (AI) HAART e.g. with
(28th)/30th– 2 x 250 mg/d p.o. ZDV + 3TC + Change of ART if therapeutic failure occurs
37th (+0) / B) HAART (BI) e.g. PI / NVP
37th (+6) with ZDV + 3TC + if possible without EFV
week of PI/NVP; or d4T+ddI
gestation if possible without
EFV or d4T+ddI
37th (+0) – Primary cesarean section or
37th (+6) vaginal delivery, only if viral load <limit of detection shortly before birth and no obstetric risks
week of (for preconditions and special management of vaginal birth see 6.)
gestation + 1 mg/kg i.v. ZDV from 3h before caesarian until separation,
during the first hour a doubled loading-dose, i.e. 2 mg/kg
no ZDV if d4T is a component of the maternal therapy
Newborn A: ZDV 4 x 2mg/kg/d p.o. for 2-4 weeks or
with a com- B: ZDV 4 x 1,5mg/kg/d i.v. for 10 days
plication-
free birth Refraining from breast-feeding
process
ZDV, zidovudine; ART, anti-retroviral combination therapy with usually three medications: two nucleosidal reverse transcriptase in-
hibitors + a protease inhibitor (PI) or nevirapine; 3TC, lamivudine; ddI, didanosine; d4T, stavudine; NVP, nevirapine; EFV, efavirenz;
VL, virus load
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women with Hepatitis B virus (HBV) co-infection
According to the German-Austrian guidelines for the
therapy of HIV1-infection in adults (30) an anti-retro-
viral three drug regimen including Tenofovir plus 3TC
or Tenofovir plus FTC, which all three have for antivi-
ral activity for hepatitisB, is also recommended for
HIV-positive pregnant women with Hepatitis B co-in-
fection. Because of alarming study results in pregnant
animals [135, see also 2.3] Tenofovir should be used
with caution in pregnancy. In the special case of HBV
co-infection in HIV-positive pregnant women the risk-
benefit analysis will more often result in the use of
Tenofovir, because of the advantage in therapy of He-
patitis B.
Interferon-alpha and pegylated interferon-alpha are
not recommended during pregnancy.
After starting anti-retroviral therapy in pregnancy a
HIV/HBV co-infected pregnant women should be
monitored at close intervals. Not later than two weeks
after start of therapy the first laboratory control has to
be performed. Thereafter monthly controls are ade-
quate.
If the anti-retroviral therapy will be ceased after
pregnancy (no maternal - but fetal indication for thera-
py) severe flare-up’s of HBV disease should be taken
into account and the close laboratory controls must be
continued after birth. In case of an indication for ther-
apy of hepatitis B-infection only, after birth a change
in therapy to drugs against HBV with no anti-HIV ac-
tivity is possible.
All infants born to HBV-infected women should re-
ceive hepatitis B immune globulin (HBIG) and initiate
the three dose hepatitis B vaccination series within 12
hours.
2.4.2 Management of HIV1-positive pregnant
women with Hepatitis C virus (HCV) co-infection
Because maternal HCV-infection increases the risk of
vertical HIV-transmission, an effective anti-retroviral
combination therapy is recommended for HCV-/HIV-
co-infected pregnant women.
An effective anti-retroviral HIV-therapy during
pregnancy also reduces mother-to-child- transmission
of HCV.
In HIV/HCV co-infected pregnant women labora-
tory examination should be performed two weeks fol-
lowing initiation of anti-retroviral therapy and then at
least monthly.
Pegylated interferon-alpha is not recommended -
and ribavirin is contraindicated during pregnancy be-
cause of teratogenicity (FDA category X).
Decisions concerning the mode of delivery in
HIV/HCV co-infected pregnant women should be
based on considerations related to HIV infection
alone.
2.5. INTERRUPTION OF ANTI-RETROVIRAL THERAPY
DURING THE 1ST TRIMESTER OF THE PREGNANCY
The decision to interrupt maternal anti-retroviral ther-
apy in the 1st trimester of pregnancy depends on the
individual clinical, immunological and virological sta-
tus of the pregnant woman as well as the anti-retrovi-
ral treatment case history. If the patient was clinically
symptomatic before the start of anti-retroviral therapy,
or if immunological and/or virological parameters
showed an advanced state of immune deficiency
and/or a very high risk for rapid disease progression,
interruption of therapy is fraught with greater risks
for the pregnant women than it is for a clinically
asymptomatic woman, whose laboratory parameters
might justify the start of an anti-retroviral therapy, but
whose clinical status is stable and whose laboratory
parameters are no cause for major immediate concern.
It must necessarily mentioned, that up to now all
randomized trials of structured treatment interrup-
tion/STI versus continuous therapy, especially the
SMART-study [139] (interruption of therapy with CD4
>350/µl and restart of therapy with CD4 <250/µl ver-
sus continuous therapy), showed a more worse out-
come in the STI-group according to cardiovascular dis-
ease, opportunistic infections, AIDS, death etc..
Vertical HIV1-Transmission occurs very rarely dur-
ing the first 12 weeks, and is most common at the end
of pregnancy and during birth. Therefore an effective
HIV1-transmission prophylaxis does not require anti-
retroviral therapy during the entire pregnancy. Since
currently adverse side effects (especially during the
organogenesis) can not be excluded, particularly with
application during the first trimester, an at most 3
month interruption of maternal anti-retroviral therapy
should be taken into consideration [133,134]. The de-
cision to interrupt anti-retroviral therapy in the first
trimester of pregnancy should be made individually
and according to individual risk profiles with the in-
formed consent of the mother. If therapy is interrupt-
ed, monitoring intervals should be short (at least
monthly measurement of t-helper cell number and the
virus load) (AII,III).
Up to now, no results of controlled trials have been
published regarding the risks associated with interrup-
tion of anti-retroviral therapy during pregnancy, and
inadequate data exist to allow any estimation of the
risk that anti-retroviral combination therapy during the
1st pregnancy trimester entails for the child [12, 57].
From an embryo-toxicological standpoint, no drugs
with unclear human teratogenic potential should be
applied in the first trimester until the 11th completed
week of gestation + 0, (after the last regular menstrua-
tion) due to their potential effects on organogenesis
[58, 59, 60].
If a decision is made in favor of therapy interrup-
tion, all anti-retroviral medications should be ceased.
In regimes consisting of 3NRTI or 2NRTI +PI the si-
multaneous interruption of all drugs can be managed
without problems.
In contrast, because of a possible long half-life up
to 3-4 weeks of NNRTI [141] with a high interindivid-
ual variability, simultaneous interruption of an anti-
retroviral combination therapy with 2NRTI+1NNRTI
(such as efavirenz and nevirapine) results in an tempo-
rary monotherapy with a high risk of development of
NNRTI-resistance. At present the most safe manage-
ment of this problem in non-pregnant individuals is to
replace the NNRTI by a (boosted) PI and cease this
EUROPEAN JOURNAL OF MEDICAL RESEARCH November 3, 2009 469
1. HIV in Pregnancy:Umbruchvorlage  15.10.2009  12:31 Uhr  Seite 469EUROPEAN JOURNAL OF MEDICAL RESEARCH 470 November 3, 2009
Table 3.2. Prevention of vertical HIV1-transmission in case of pregnancy - and birth complications.
Pregnancy Complication-free Viral load • Premature labor • AIS/amnionitis Viral load increase at
complication: (multiple) pregnancy shortly before • premature birth in • premature birth the end of a pregnancy
and viral load shortly birth ≥ 33rd(+0) - 36th < 33rd (+ 0) GW >10 000 HIV copies/ml
before birth <3 000 3 000 -10 000 (+6) GW e.g. because of lacking
HIV copies/ml HIV copies/ml prepartal prophylaxis
HIV1-trans- Normal Raised Very high
mission risk
Measures in Mutliple pregnancy: - Tocolysis,
the24th(+0)– Prophylaxis onset - if necessary antibiotics
37th (+0-6) brought forward with - RDS-prophylaxis
week of ZDV or ART after GW - HAART e.g.:ZDV+
gestation 29(+0) because of the 3TC + PI/NVP
risk of premature birth (if possible no EFV or
d4T+ddI)
Birth: (Elective) Primary Only (Elective) CS !! If still possible (de- Elective CS
37th (+0) – 37th cesarean section/CS cision dependent of
(+6) week of or vaginal delivery + 1 mg/kg i.v. ZDV starting 3 h before obstetrical situation)
gestation (the latter only if viral cesarean until birth, during the first hour a cesarean within 4h
load <limit of doubled loading-dose, i.e. 2 mg/kg after rupture of
detection shortly membranes
before birth and no
obstetric risks / for + 1 mg/kg i.v. ZDV from 3 h before cesarean
management of until birth, during the first hour a doubled
vaginal birth see 6.) loading-dose, i.e. 2 mg/kg
+ 1 mg/kg i.v. ZDV
starting 3 h before Prepartal 1x 200mg NVPﾰ in addition to the
cesarean until birth, ongoing ZDV prophylaxis or ART
during the first hour a ZDV prophylaxis or ART
doubled loading-dose,
i.e. 2 mg/kg
Postnatal 4 weeks: 6 weeks: 6 weeks:
prophylaxis Dosing with A) Dosing with newborns + premature ZDV 4x 2mg/kg/d (note premature born
of the newborns: babies ≥ 36th (+0) GW: dosing) + 3TC 2x 2mg/kg/d*
newborn ZDV 4x 2mg/kg/d p.o. ZDV 4x 2mg/kg/d p. o.
(108): B) Dosing with premature babies A) with successful prenatal NVP application ﾰ a
Refraining from < 36th (+ 0) GW (109): further NVP dose with the newborn (2mg/kg)
breast-feeding 2x2mg/kg/d p.o. (or 2x 1.5mg/kg i.v.) at an age of between 48-72h
Dosing with premature babies
> 30th (+0) GW: B) If NVPﾰ is not given prepartally, two NVP do-
from 3rd week of life ses (each 2mg/kg) postnatally to the newborn:
increase to 3x 2mg/kg/d p.o. 1st Dose as soon as possible after birth,
Dosing with premature babies 2nd Dose on the 3rd day of life
≤ 30th (+0) GW: (cave: because of enzyme induction faster
from 4th week of life: elimination of NVP in the newborn, if NVP
increase to 3x 2mg/kg/d p.o. was a omponent of the maternal therapy
during pregnancy)
Refraining from breast-feeding
Refraining from breast-feeding
Birth com- - Incision injury to the child
plications: - Oral intake of bloody amniotic fluid into gastrointestinal or
respiratory tract of the newborn
HIV1-trans- Very high
mission risk
Postnatal 6 weeks:
measures in ZDV 4x 2mg/kg/d (check premature born dosing wherever necessary) + 3TC 2x 2mg/kg/d*
the newborn:
Two postnatal NVP dosesﾰ (each 2mg/kg) to the newborn:
1st Dose as soon as possible after birth,
2nd Dose on the 3rd day of life
(cave: because of enzyme induction faster elimination of NVP in the newborn, if
NVP was a component of the maternal therapy during pregnancy)
Refraining from breast-feeding
* Beware: Presently only a few clinical results have been published regarding the application and dosing of lamivudine with (extreme) pre-
mature infants.
ﾰ Beware: if the HIV1-positive expectant mother has been treated for a longer period of time with nevirapine during pregnancy, an enzyme
induction may occur that may lead to a more rapid breakdown of nevirapine in the newborn.
ZDV, zidovudine; ART, anti-retroviral combination therapy usually with three medications: two nucleoside reverse transcriptase inhibitors + one pro-
tease inhibitor (PI) or nevirapine; 3TC, lamivudine; ddI, didanosine; d4T, stavudine; NVP, nevirapine; EFV, efavirenz; AIS, amnion infection syndrome
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native the 2NRTI are continued over 4 weeks after
stopping NNRTI (if possible under monitoring the
NNRTI-level via therapeutic drug monitoring) [29,
122]. Because a pregnancy is usually observed not be-
fore some weeks after conception, an additional 4
weeks lasting procedure to interrupt a regimen with
2NRTI+NNRTI interferes with the avoidance of these
drugs during organogenesis. Therefore a prompt inter-
ruption of NNRTI-containing regimens can hardly be
arranged in the first 6-8 weeks of gestation (where
most organs develop) and therefore can not be recom-
mended. Nevertheless an interruption of a combina-
tion with NNRTI in the remaining weeks should be
guided by an HIV-experienced infectious disease spe-
cialist to minimize the development of drug resistance.
The anti-retroviral treatment should not be re-
sumed before the 13th (+0) week of pregnancy in or-
der to take into account the uncertainties in the exact
time of conception.
If a woman under anti-retroviral therapy has
planned for a child, a pregnancy test (HCG) should be
undertaken very early on. The pregnancy test be-
comes positive 6-8 days after conception, thus a deci-
sion to interrupt anti-retroviral therapy can be made
accurately in time. On the other hand because the
time until conception cannot be calculated and can
last very long an anti-retroviral therapy should never
be stopped before conception even when the preg-
nancy is planned.
If a HIV1-positive women plans to get pregnant, if
possible no Efavirenz containing ART should be start-
ed or Efavirenz containing regimes should be changed
to regimens with other components (for example
boosted PI, Nevirapine) in time.
After interruption in the first trimenon therapy with
the same drugs can be restarted (exceptions: efavirenz,
combination of stavudine + didanosine, provided that
therapeutic alternatives are available) [45, 46], since re-
sistance development is not to be expected [32, 33]
(AII,III).
These recommendations also apply if pregnancy is
first diagnosed during the course of the 1st trimester.
3. HIV1-TRANSMISSION PROPHYLAXIS WITH
STANDARD RISK PROFILE (SEE TABLE 3.1)
Prophylactic scheme (= no maternal treatment indica-
tion, criteria see table 3.1!!!!):
3.1a) Viral load in the expectant mother < 10,000
genome copies/ml:
In this situation two alternative regimens can be used:
I. Zidovudine application from the completed 30th
(or 28th) (+0) GW at an oral dose of 2x250 mg.
II.Temporary anti-retroviral combination therapy with
3 drugs (HAART, but if possible no Efavirenz) from
week of gestation 30+0 (28+0) until immediately af-
ter birth
Comments to oppurtunity I:
Provided that there is no primary resistance to zidovu-
dine, a reduction of viral load at birth can be achieved
under a zidovudine-monoprophylaxis from a low ini-
tial virus load. This suffices - particularly in combina-
tion with a planned cesarean birth - for minimizing the
risk of transmission to the child [5, 71, 72, 124, 131,
132]. The advantage in comparison with HAART is
the lower risk of prophylaxis-associated toxicity for
mother and child. Because of the short duration of
this monoprophylaxis and of the comparatively high
resistance barrier of zidovudine the risk of developing
a resistance against zidovudine should be very low [68,
115]. In comparison to HAART the risk in monopro-
phylaxis (provided a good adherence to both regi-
mens) is higher that viral load is not reduced suffi-
ciently until birth.
Comments to oppurtunity II:
Under a temporary standard anti-retroviral therapy
(HAART) from week of gestation 30+0 (28+0) until
immediately after birth the low viral load can be de-
creased under limit of detection at birth with a high
probability [5, 71, 130, 131, 132]. Because of the long
half life (which can induce resistance during a cessa-
tion after birth) and increased toxicity in patients with
CD4-cells higher than 250/µl, this prophylactic
HAART should not contain Nevirapine. Ideal for pro-
phylaxis are regimens with a (boosted) PI [29]. Provid-
ed a good adherence the risk of induction of a drug
resistance is lower than in a monoprophylaxis with zi-
dovudine. Disadvantage of a prophylaxis with HAART
is the higher drug burden for mother and child, which
can lead to more adverse effects and toxicities than in a
monoprophylaxis. These complications can reduce ad-
herence and then result in development of drug resis-
tance [114]. On the other hand changed pharmacoki-
netics of anti-retrovirals in pregnancy (published for
Indinavir; for many other anti-retroviral drugs no phar-
macokinetic data in pregnancy exist) can induce drug
resistance [41, 61, 62, 63, 64, 65, 66, 68, 69, 70, 113].
In the decision to use a monoprophylaxis with zi-
dovudine or HAART in pregnant women with a viral
load < 10,000 genome copies/ml also the elevated rate
of prematurity under HAART, which increases verti-
cal transmission of HIV, must be taken into account
[101, 115, 116].
3.1b) viral load in the expectant mother>10,000HIV-
genome copies /ml:
The risk of vertical transmission is directly propor-
tional to the viral load in the pregnant women. If there
is not yet a distinct maternal indication for treatment
(CD4 cell count >350/µl), but the viral load is higher
than 10,000 virus copies/ml, a temporary anti-retrovi-
ral standard combination prophylaxis (without efa-
virenz !) is recommended from GW 30 +0 (or 28 + 0)
to immediately after delivery, since a zidovudine
monoprophylaxis is not able to reduce the viral load
with adequate certainty (raised risk of transmission
with VL > 10,000 [5, 62, 71, 72, 73, 74] (AI,II).
In case of a very high viral load (>100 000HIV-
copies/ml) a start of anti-retroviral prohylaxis can
considered in GW 28+0. The early start of prophylax-
is allows for controls of success of anti-retrovirals at
an early stage (e.g. in GW 32+0). If a change of anti-
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for the new regimen there is enough time until birth to
suppress viral load as much as possible.
3.2 Primary cesarean section, available between 37
(+0) to 37 (+6) gestational week utilizing an operation
technique which avoids excessive bleeding, performed
rapidly by the most experienced obstetrician [75,76].
The benefit of the elective cesarean section for trans-
mission prophylaxis in patients under an anti-retroviral
combination therapy or prophylaxis with a low viral
load in the plasma, is not evidenced and is still a mat-
ter of dispute (see point 6 for a detailed discussion of
the mode of birth) (AI,II).
3.3 Pre- and intra-operative intravenous zidovudine
application starting 3 hours before cesarean section (2
mg/kg as a loading-dose for 1 hour followed by 1
mg/kg until the delivery of the child according to the
original ACTG 076 protocol), even if zidovudine is
not a component of the maternal therapy/ prophylax-
is during the pregnancy [77] (AI).
3.4 Postnatal zidovudine application for the child over
2-4 weeks orally (2 mg/kg every 6 hours) or 10 days
i.v. (1.5 mg/kg every 6 hours) [78] (AI).
Since a higher prevalence of zidovudine-resistant
HIV1-strains can be expected in the future [40], the
presence of wild-type HIV1 should be confirmed
genotypically in the expectant mothers before zidovu-
dine is applied (exclusion of genotypic resistance).
4. RISK-ADAPTED TRANSMISSION PROPHYLAXIS
(SEE TABLE 3.2)
For birth-related HIV1-transmission risks, HIV1-
transmission prophylaxis should be escalated in a risk-
adapted manner.
4.1 Multiple pregnancy, premature labor and prema-
ture infants 33rd(+0) - 36th(+6)GW and maternal vi-
ral load 3 000- 10 000 HIV-copies/ml before birth
Because of the increased risk of premature birth in
multiple pregnancies, prophylactic zidovudine applica-
tion should already be started from the 29th (+ 0)
week of gestation (AIII).
In case of premature labor, anti-retroviral combina-
tion prophylaxis should be started immediately (with
e.g. zidovudine + lamivudine + PI), if the pregnant
women is not yet receiving a combination therapy, if a
cesarean birth is not indicated because of immaturity
of the baby and if labor can still be stopped (AIII).
If a premature birth is unavoidable, the procedure
described in 4.2 should be followed.
If e.g. because of a premature delivery etc. the viral
load of the mother is between 3 000 – 10 000 HIV-
copies/ml before birth, the postnatal prophylaxis
should be prolonged according to the ACTG 076-
study protocol, where zidovudine is applied over 6
weeks orally [14,63]. The newborn should be closely
monitored during this prolonged prophylaxis. If prob-
lems such as anemia, neutropenia or lactate acidosis
occur, benefits and risks of continuing the prophylaxis
should be carefully weighed, and in doubt prophylaxis
should be discontinued (A/III).
4.2 Amnion infection syndrome/amnionitis, prema-
ture rupture of membranes > 4h, premature birth
<33rd(+0) GW and viral load increase at the end of
pregnancy >10 000HIV copies/ml
In these obstetric emergency situations the transmis-
sion risk is greatly increased [3, 5, 15, 16, 72, 79, 132].
The prepartal part of the prophylaxis should (as long as
a standard combination therapy/prophylaxis is not al-
ready being given) be intensified by an (additional) dose
of nevirapine as long as this is still possible [83].
Postnatally, transmission prophylaxis can also be es-
calated in the newborn through application of nevi-
rapine in addition to a combination prophylaxis with
zidovudine + lamivudine [82, 83, 84]. In this case one
dose of nevirapine should be given to the newborn af-
ter 72h if the mother has already received one dose
prepartally (minimum 2hours before birth). Two doses
should be given if the mother did not receive a
prepartal dose or if less than two hours have elapsed
between nevirapine application to the mother and
birth [56, 81, 83]. If two doses are given, the first
should be given immediately -and the second within
72h after birth (AI,III).
Under nevirapine ultrashort monoprophylaxis (one
dose of nevirapnie shortly before birth) there is a con-
siderable risk of resistance development in the mother
(>20%). To reduce this risk either continuous combi-
nation therapy (in the case of treatment indications
for the mother) or transient combination therapy - e.g.
additional 2 NRTI’s over a period of 1 week after oral
nevirapine should be considered as a possible protec-
tive measure against resistance development (see also
the strategies described under 2.5/therapy interrup-
tion). So far no evidence base for this strategy.
2-4 weeks after termination of transient combina-
tion therapy or ultrashort monoprophylaxis it should
be evaluated, whether resistance has been induced by
resistance testing.
If the HIV1-positive expectant mother was treated
with nevirapine for a longer period during the preg-
nancy, an enzyme induction might result in the new-
born so that a more rapid breakdown of nevirapine
occurs [53]. For this reason, with longer nevirapine
therapy of expectant mothers during pregnancy, the
drug must be applied at higher doses to the newborns
(4 mg/kg).
The preferred mode of delivery is immediate ce-
sarean section if the rupture of membranes does not
already date back longer than 4 hours. For intervals
>4 h after (premature) rupture of membranes, no ad-
vantage of cesarean section regarding transmission
risks can be expected [85]. However, the decision to
implement this must be based on obstetric considera-
tions.
Rupture of membranes between the 24th and 28th
gestational weeks represents a particularly problematic
special case. Steroid induced pulmonary maturation in
the unborn is not effective before 24 hours after appli-
cation and therefore contradicts measures required for
preventing HIV1-transmission. In this case the high
risk of permanent damage to the child due to lacking
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mission rate must be carefully weighed up.
4.3 INCISION INJURY TO THE CHILD/ ASPIRATION
AND/OR INGESTION OF BLOODY AMNIOTIC FLUID
With an incision injury to the child during caesarian
section, or if bloody amniotic fluid can be aspirated
from the stomach and/or the lungs, a percutaneous in-
oculation or a mucosal exposure to virus-containing
body fluids must be assumed [23]. This justifies an in-
tensification of the usual standard pediatric prophy-
laxis to a combination prophylaxis consisting of two
NRTI-s consistent with post-exposure prophylaxis
recommendations for adults [86] (AIII). An extended
application of nevirapine (exceeding the ultra-short
prophylaxis) for post-exposure prophylaxis can not be
recommended at this time because of the lack of data
regarding pharmacokinetics and safety.
Because of the lack of experience and formal ap-
proval of protease-inhibitors and NNRTIs for the
therapy of newborns, and because of the dearth of
comparative studies on the efficacy of double NRTI
and triple drug post-exposure prophylaxis regimens,
the recommendations for treatment escalation are lim-
ited to measures that have been proven effective and
tolerable within the context of mother-to-child trans-
mission prophylaxis. For these reasons the postexposi-
tional prophylaxis of newborn with high risk of HIV-
transmission should be limited to two NRTI’s com-
bined with one or two doses Nevirapine.
5. PROCEDURES WITH INCOMPLETE
TRANSMISSION PROPHYLAXIS
5.1 WITH VERIFIED HIV1-INFECTION
If despite of a known HIV1-infection no transmission
prophylaxis has been carried out until the time of
birth, this should be done at the latest during delivery
and postnatally. A benefit for the newborn can even
be expected with incomplete transmission prophylaxis
[63,64,87,88,89]. A combination of a nevirapine ultra-
short prophylaxis (one dose prepartally for the moth-
er, one dose postnatally for the newborn or 2 doses
postnatally) with a six-week zidovudine or zidovudine
+ lamivudine application for the newborn is then rec-
ommended (AI).
According to data from the HIVNET 012 study, a
single dose of nevirapine shortly before birth com-
bined with a single dose given to the newborn within
72 hours of birth is more effective in preventing verti-
cal transmission than the immediate pre- and intra-
partal administration of zidovudine combined with a
week long postnatal administration of zidovudine to
the newborn [87]. (Measures of maternal short time
nevirapin prophxlaxis see also 4.2)
Zidovudine prophylaxis started within 48 hours af-
ter birth according to the ACTG 076 protocol (appli-
cation over 6 weeks) can still lower the HIV1-trans-
mission rate. In a retrospective US study a transmis-
sion rate of 9.3 % has been reported with initiation of
zidovudine therapy in the first 48 hours after vaginal
delivery, as compared to a rate of 18.4% for a later on-
set of therapy (>48 h). Without any therapy, 26.6 % of
the children became infected[64].
5.2. SITUATION WITH AN UNCLEAR HIV1-INFECTION
STATUS
If a patient presents late in her third trimester without
HIV-Test and sufficient time remains to perform a
screening test (and if necessary a confirmatory test),
this should be offered without delay, so that intrapartal
and postpartal transmission prophylaxis can be carried
out whenever the test proves positive [64].
The HIV-antibody test should be accompanied by
competent personal counseling, provided if necessary
by an appropriate institution [1,2]. The refusal to un-
dergo HIV-antibody testing must be respected.
In cases when the HIV status of the pregnant
women is unknown and there is no time to carry out
regular testing and counseling, an HIV-rapid test
should be offered and prophylactic measures can be
instituted with positive rapid test results. During coun-
seling the pregnant women about HIV-rapid tests, it
should considered, that in spite of accurateness of
these tests (sensitivity and specificity of HIV-rapid
tests achieve results of >99,5%) the probability, that a
positive HIV-rapid test is positive in confirmatory
tests can be less than 50% in the view of the low
prevalence of unknown HIV1-infections in pregnant
women (estimated about 50-100 cases per 200.000-
300.000 untested pregnant women until 2007). There-
fore every positive HIV-rapid test must be confirmed
by HIV-Elisa or HIV-Westernblot. If the confirmation
fails, all measures to avoid HIV1-transmission must be
ceased immediately.
An opportunity to further increase the specificity
arises from controlling a positive rapid test finding
with a second rapid test procedure. If the second test
reports a negative finding, the probability is high that
the first test result was false positive.
6. MODE OF DELIVERY
Studies, analyzing HIV1-positive pregnant women and
their children before the beginning of the HAART-
era, showed a significant reduction of mother-to-
child-transmission of HIV1 by a primary cesarean sec-
tion. Delivery by elective cesarean section (before the
onset of labor) resulted in a reduction of the vertical
transmission risk by approximately 50%, i.e. in a 8.2%
vs. 16.8% risk associated with vaginal birth[76]. Elec-
tive Cesarean section should therefore represent an es-
sential component of every prophylactic HIV1-trans-
mission regimen (AI,II). On the other hand some
studies which compared healthy pregnant women with
HIV1-infected pregnant women showed a higher rate
of complications as cause of cesarean section (e.g.
higher rates of fever, hematoma and wound infection
[117, 118, 139]) in HIV1-positve women. In contrast
other studies failed to prove these disadvantages of
cesarean section [97, 98, 99, 100].
According to recent examinations the protective ef-
fect of cesarean section in HIV1-positive women, who
were treated with HAART in pregnancy and whose
HIV-viral load was under limit of detection at the end
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Hence a vaginal delivery is arguable under these opti-
mal conditions (HAART in pregnancy, HIV-viral load
in pregnancy especially shortly before birth under limit
of detection), when it is the request of the pregnant
women and no obstetric risks argue against it.
Practical procedure in the delivery room:
Preoperative/ intra-operative i.v. zidovudine thera-
py of the mother at a dose of 1 mg/kg/h after a load-
ing-dose of 2 mg/kg over 1 hour until delivery still
represents a prophylactic measure independently of
mode of delivery (AI, AII).
a) The elective, primary cesarian section should be
carried out by the most experienced obstetrician avail-
able utilizing an operation technique which avoids ex-
cessive bleeding, performed between 37 (+0) to 37 (+6)
gestational week on a labor-free uterus under i.v. appli-
cation of zidovudine. Because of lower maternal com-
plications (pneumonia/fever) and the possible early
bonding in delivery room a local anesthetic procedure
(e.g. spinal anesthesia) is preferably recommended [97].
b) To keep the risk of vertical HIV1-transmission
as low as possible during an intended vaginal delivery
some special features have to be considered:
Invasive monitoring of the newborn (sampling of
microbloodprobes from fetal scalp, scalp electrodes
etc.) should not be used. A maybe necessary amnioto-
my has be performed as late as possible. An operative
vaginal delivery should be avoided. Especially in case
of protracted labour, abnormal fetal heart rate or sus-
picion of AIS/amnionitis etc. the indication/decision
for a (secondary) cesarean section should be taken into
account generously and earlier as usual.
It should be noted that an increased rate of prema-
ture birth has been documented on several studies in
mothers treated with an anti-retroviral combination
therapy [101]. However, two large American studies [5,
36] failed to find an increased rate of premature birth
under HAART. Considering these contradictory find-
ings, in the last trimester special attention must be paid
towards women with anti-retroviral combination ther-
apy or other risk factors for premature birth so that a
premature birth or other emergency mode of birth
under unfavorable conditions can be avoided. This is
warranted by frequent antepartum controls in the
third trimester and, under certain conditions, early
hospitalization.
It is urgently recommended that an HIV post-expo-
sure prophylactic emergency set be kept in stock by
the hospital and that all medical personnel involved is
informed about an emergency plan including indica-
tions and procedures related to HIV post-exposure
prophylaxis (PEP) after occupational HIV exposure
(e.g. following needle prick or knife injuries to the op-
erating surgeon). For actual German-Austrian PEP
guidelines see www.daignet.de under HIV-therapy.
7. CARE OF THE NEWBORN IN THE DELIVERY
ROOM
Amniotic fluid can be contaminated with HIV1 by the
opening of the amniotic sac during both a sponta-
neous delivery and a cesarean section. With a vaginal
delivery there is also the possibility that virus-contain-
ing vaginal secretions or maternal blood gain access to
the body openings of a child [23, 93]. Unlike adults,
the mucous membranes of the respiratory and gas-
trointestinal tracts do not represent barriers to HIV1
in the newborn, and the still anacidic stomach can fail
to inactivate the virus. Higher transmission rates from
HIV1-infected mothers to breast-fed (as opposed to
bottle-fed) children confirm that the oral uptake of
virus-containing fluids plays a considerable role in ver-
tical transmission [102].
Practical procedure in the delivery room:
The use of sterile gloves is recommended for initial
treatment. Before suction of the mouth, the oral cavi-
ty and the nostrils should be cleaned of any potentially
HIV1-contaminated amniotic fluid using sterile swabs
soaked in 0.9% physiological saline. After stabilization
of vital functions, all body openings (ears, eyes, anus
and genitals) should be cleaned in the same way.
Before the final severance of the umbilical cord,
gloves must be changed in order to avoid any HIV1-
contamination of the umbilical stump (AIII).
8. POSTNATAL TRANSMISSION PROPHYLAXIS IN
CASE OF STANDARD RISK
The recommendation of oral zidovudine application
over 6 weeks to the child at a dose of 2 mg/kg every 6
hours results from the findings of the ACTG 076 study
[14]. After oral zidovudine application during pregnan-
cy, intravenous zidovudine infusion during birth, and
elective cesarean section, this represents the fourth
component of HIV1-transmission prophylaxis. A de-
escalation of the six-week postnatal component (ac-
cording to the ACTG-076 protocol) of the transmission
prophylaxis is justified by the results of a study carried
out in Thailand involving a shortened zidovudine regi-
men and considering experience gained in Germany
until now. The Thai study showed that the six week
therapy produced an additional benefit as compared to
a three day postnatal zidovudine dosing when the dura-
tion of prepartal prophylaxis was very short (from the
36th week of gestation with spontaneous delivery as
the predominant mode of birth) [63]. In Berlin, satis-
factory results (no transmissions) have been achieved
(involving a small number of cases, n = 57 [78]) with an
i.v. dosing of 1.3 mg/kg every 6 hours over 10 days if
the prepartal prophylaxis was started in the 32nd week
of gestation. The majority of experts conclude from
this that postnatal zidovudine should be given to the
child, although they consider a reduction of the dura-
tion of postnatal zidovudine transmission prophylaxis
to 2 to 4 weeks (2 mg/kg orally every 6 hours) as usual-
ly sufficient (AI,III). Exceptions to this rule include
pregnancy and birth complications as well as failure to
implement a maternal prophylaxis (see 4.2, 4.3 and 5.1).
9. REFRAINING FROM BREAST FEEDING
Breast-fed children of HIV1-positive mothers are in-
fected twice as frequently as formula-fed children of
HIV1-infected mothers. The HI viruses and HIV1-in-
fected lymphocytes detectable in breastmilk as well as
inflammation/injuries of the nipple or the mammary
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tion/ blood contribute to this raised infection rate.
The WHO therefore recommends that babies of
HIV1-infected mothers should be fed with formula
food in industrialized countries with clean drinking
water. All HIV1-positive mothers should therefore be
urged to avoid breast feeding [103,104,105] (AI,II).
10. POSTNATAL CARE OF THE HIV1-EXPOSED
CHILD AND PREPARATION OF A SURVEILLANCE
REGISTER
From the 32nd week of gestation IgG antibodies, in-
cluding also IgG antibody against HIV1, are transmit-
ted from the mother to the fetus across the placenta.
Since the conventional HIV1 test is an antibody test,
all, i.e. even non-infected children of HIV1-infected
mothers, are serologically HIV1-positive until the ma-
ternal antibodies disappear.
Detection of HIV1 during the first two years of life
must therefore be completed using HIV1-PCR based
methods. It is possible to detect either HIV1-DNA or
HIV1-RNA. Up to now it is unclear which test proce-
dure is the more sensitive with respect to the special
situation of neonatal infection diagnostics. All positive
HIV1 test results should be confirmed as rapidly as
possible by a second blood test.
It should be noted that commercially available
HIV1-PCR kits do not cover all HIV1-subtypes or
mosaic viruses (not subtype B) and may provide false
negative results [106]. With an HIV1-positive parent
that might be infected with a subtype other than B (es-
pecially if the patient originates from outside Western
Europe / North America), maternal blood must al-
ways be analyzed as a positive sample in addition to
the child’s blood (if possible before the onset of an
anti-retroviral therapy/ prophylaxis of the mother!).
If the maternal blood is unambiguously HIV1-posi-
tive in the PCR, the result of the HIV1-PCR of the
child should also be utilized. If the detection of HIV1-
nucleic acids fails with maternal blood (negative or
borderline findings), the HIV1-PCR analysis of the
child’s blood can not be relied upon. Then, either a
special examination must be initiated using subtype-
adapted PCR primers in specialized laboratories, or the
disappearance of the maternal HIV1-antibody at the
end of the 2nd year of life must be waited for in order
to reliably exclude an HIV1-infection in the child.
If the HIV1-antibodies in the HIV1-exposed child
persist, an HIV1-infection must be assumed. As a mat-
ter of definition, HIV1-exposed children are regarded
as HIV1-negative if an HIV1-Western blot proves
completely negative with normal immunoglobulin
concentrations.
Amongst children of HIV1-positive mothers, two
negative HIV1-PCR findings are required to exclude
an HIV1-infection. The first HIV1-PCR should be
performed one month after birth (in the age of 28
days: sensitivity 96%, specificity 99%[129]); the second
one after the third month of life, because at this time-
point the sensitivity and specificity of the HIV1-PCR
is considered to be sufficiently high [107].
With the HIV1-PCR test in the first month of life a
high rate of HIV1-infected children can be diagnosed.
This is important for starting prophylaxis against
Pneumocystis carinii as early as possible (if possible 4-
6 weeks after birth where HIV1-transmission has oc-
curred) and the early-life anti-retroviral therapy in the
first months of life.
With negative HIV1-PCR findings as well, disap-
pearance of maternal antibodies in HIV1-exposed
children should be documented at least once.
It must be stressed here that because of the in-
trauterine and postnatal exposure of a child to anti-
retroviral substances with still unknown long-term
consequences, clinical surveillance of the children is
indispensable to get aware of any long-term damage.
11. HOTLINE, NOTIFICATION OF UNEXPECTED
OBSERVATIONS AND EXPERIENCES
Honorary telephone hotline
for problems regarding HIV infection during pregnan-
cy and in HIV1-exposed newborn:
Gynecologic problems: 0178 - 282 0 282
HIV-therapy in pregnancy: 0178 – 673 1661
Pediatric problems: 0178 - 41 21 313
Further updating of the recommendations:
Since only little or even no results or information are
available regarding the application of newer drugs or
combinations of drugs during pregnancy or in new-
borns, all physicians involved in this work are urgently
invited to inform us of any new or unexpected obser-
vations and results, e.g. by notifying us by e-mail at the
address given in the ”address for correspondence”, or
by notifying the "anti-retroviral Pregnancy Registry"
(APR), the largest register for recording experiences
with anti-retroviral substances during pregnancy:
Tel-no.: +1-910-256-0238
Fax: +1-910-256-0637 or +44 1895 825 005
Website: www.APRegistry.com
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